MedTrace Logo

Incidence of Complications of Peripheral Venous Access in the Type 2 Diabetic Population

NCT04499638 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2025-02-25

No results posted yet for this study

Summary

Diabetes Mellitus type 2 (T2DM) is one of the most frequent metabolic diseases worldwide. It is expected that in 2035 around 600 million people will suffer from the disease. A recent systematic review has estimated that the direct annual cost of Diabetes worldwide treatments and care is over $ 827 billion and has been independently associated with nosocomial complications, thrombosis-like infections and prolonged admissions. In addition, it is estimated that up to 90% of patients in acute hospitals require a peripheral venous catheter which are associated at the same time with mechanical, infectious and thrombotic acute complications. Recently the emergence of new medium-sized peripheral devices (Midline®) and new peripheral central venous access catheters (PICC), which are more biocompatible, are opening new clinical possibilities with the aim of improving safety and comfort during treatment time and the reduction of associated complications.

With all this, an observational case-control study has been proposed in order to analyse the impact of T2DM disease and its associated complications on the patient requiring peripheral venous access. Furthermore investigators will consider if these new peripheral devices can be a remarkable benefit for these patients. This study will be carried out at the Vall d'Hebron University Hospital in Barcelona, Spain

Conditions

  • Diabetes Mellitus, Type 2
  • Catheterization, Peripheral
  • Upper Extremity Deep Vein Thrombosis
  • Catheter-Related Infections
  • Diabetes Complications

Interventions

DEVICE

Peripheral vascular catheters

Carry time of common peripheral vascular devices in clinical practice and the reason for his withdrawal

Sponsors & Collaborators

  • Hospital Universitari Vall d'Hebron Research Institute

    lead OTHER

Principal Investigators

  • Rafael Simó, Prof. · Vall Hebron Research Institute-VHIR

Eligibility

Min Age
40 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2021-01-30
Completion
2021-05-15

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04499638 on ClinicalTrials.gov